Principal Investigators


GURNEY, MARK E

Institution


TETRA DISCOVERY PARTNERS, INC.

Contact information of lead PI


Country


USA

Title of project or programme


PDE4D Allosteric Modulators for Treating Cognitive Impairment

Source of funding information


NIH (NIA)

Total sum awarded (Euro)


€ 0.92

Start date of award


15/06/2012

Total duration of award in years


3

Keywords


phosphodiesterase 4D, mild cognitive impairment, Impaired cognition, Alzheimer's Disease, phosphoric diester hydrolase

Research Abstract


DESCRIPTION (provided by applicant): Alzheimer’s disease (AD) is an increasing medical burden due to the aging demographics of the US population. The most common form of dementia among older adults, AD affects parts of the brain important for memory formation and retrieval, seriously impairing a person’s ability to live independently and cope with daily activities. In collaboration with the NIH Blueprint Neurotherapeutics Program, we seek to develop phosphodiesterase Type 4 (PDE4) allosteric modulators for improving cognition in accordance with the Target Product Profile below. Ideally, the therapeutic will improve cognition in MCI patients and impact AD pathophysiology, thereby slowing conversion to probable AD. Drug PropertiesMinimum Acceptable ResultIdeal ResultPrimary Drug IndicationImprovement of cognition in persons with Mild Cognitive Impairment (MCI) due to probable ADSlowing of conversion from MCI to probable ADPatient PopulationPatients with MCI due to probable AD according to the NIAA/AA working group criteriaPatients with MCI due to probable AD according to the NIAA/AA working group criteriaDelivery ModeOralOralTreatment DurationChronicChronicRegimenOral, once dailyOral, once daily

Further information available at:

Export as PDF